BG NEWS ! Medtronic launches SenSight™ Directional Lead System for Deep Brain Stimulation(DBS) therapyin India

Kolkata, India August 2022: IndiaMedtronic Private Limited, a wholly ownedsubsidiary of Medtronic plc (NYSE:MDT), today announced the launch of SenSight™ directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy.Deep brain stimulation (DBS) is a treatment for symptoms of Parkinson's disease, including tremors, stiffness, and trouble walking.

Parkinson’s disease is a progressive disorder that eventually causes severe disability dueto the increasing severity of treatment-resistant motor problems and non-motorsymptoms In 2016, it was estimated that 6.1 million people worldwide had Parkinson’s disease. The prevalence in India was estimated to be 10% of the global burden, that is, 5.8 lakhs.1DBS is a therapy in which a small pacemaker-like device sends electrical signals through very thin wires, known as ‘leads’ to a targeted area in the brain related to the symptoms.

SenSight™ directional lead systems were first recently implanted in India by multi-disciplinary teams from Aster Hospitals in Bangalorecomprising of Dr Ravi Gopal Varma-DirectorGlobal Center of Excellence in Neurosciences & Lead ConsultantNeurosurgeon, Dr Mirza Masoom Abbas-Neurologist & Movement Disorders Specialistand Dr Nirmala S-Consultant Neurosurgeon. This was implanted in a 60-yr old male patient suffering from symptoms of Parkinson’s Disease for last 8-9 years.